Preparation of a transdermal delivery system and effect of membrane type for scopolamine drug

被引:0
作者
Arabi, H [1 ]
Hashemi, SA [1 ]
Ajdari, N [1 ]
机构
[1] Iran Polymer & Petrochem Inst, Fac Sci, Dept Polymer Biomat, Tehran, Iran
关键词
transdermal; drug; membrane; delivery; scopolamine;
D O I
暂无
中图分类号
O63 [高分子化学(高聚物)];
学科分类号
070305 ; 080501 ; 081704 ;
摘要
The aim of this study was to clarify the performance of a membrane controlled reservoir system (MCRS) for scopolamine hydrobromide (SH) under in vitro condition by determination of the role of membrane on SH rate control. In this method SH was incorporated into two polymers (polyisobutylene and polybutyl acrylate) and SH rate across ethylene-vinyl acetate copolymer (EVA) and ethyl cellulose (EC) membranes were measured. The results obtained showed that in the EVA membrane, the permeability of SH across membrane increased with the increase of vinyl acetate percentage in copolymer. Microscopic studies of EVA membrane surface showed that the size of surface porosity increases with the increase of vinyl acetate percentage in the copolymer and according to the results obtained, it showed an increase in drug's release rate. In the case of EC membrane, the results showed that the rate of release increases with the increase of porosity size of EC surface despite of having high molecular weight.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 18 条
[1]   STABLE ISOTOPE METHOD FOR STUDYING TRANSDERMAL DRUG ABSORPTION - THE NICOTINE PATCH [J].
BENOWITZ, NL ;
CHAN, K ;
DENARO, CP ;
JACOB, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) :286-293
[2]   METHODS FOR INVITRO PERCUTANEOUS-ABSORPTION STUDIES .4. THE FLOW-THROUGH DIFFUSION CELL [J].
BRONAUGH, RL ;
STEWART, RF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (01) :64-67
[3]  
BUSKIRK GA, 1997, PHARMACEUT RES, V14, P7
[4]  
CHEIN YW, 1991, STP PHARMA SCI, V1, P1
[5]  
CHEN YW, 1987, TRANSDERMAL CONTROLL
[6]  
DMELLO M, 1995, SCRIP REPORTS OCT
[7]  
FINNIN BC, 1999, J PHARM SCI, V88, P10
[9]   Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol [J].
Guyot, M ;
Fawaz, F .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 204 (1-2) :171-182
[10]  
HOUZE D, 1999, P INT S CONTR REL BI, V26